Largest gene therapy trial for cystic fibrosis begins

March 16, 2012
The trial will see patients 'breathe in' the gene therapy using a nebulizer.

(Medical Xpress) -- British scientists are to carry out the largest trial anywhere in the world of a gene therapy for cystic fibrosis.

A consortium of researchers from Oxford University, Imperial College London and the University of Edinburgh will start enrolling patients on the trial this month.

The UK Cystic Fibrosis Gene Therapy Consortium hopes that the study will show for the first time whether the gene therapy they have developed can improve the health of patients. The phase two clinical trial will involve 130 cystic using an to breathe in a working copy of the cystic fibrosis gene once a month for a year.

The trial will go ahead thanks to £3 million in funding from the Medical Research Council (MRC) and the National Institute for Health Research (NIHR) that is announced today.

Additional laboratory studies to develop a potentially more efficient delivery method for the gene therapy will receive a further £1.2 million in support from the MRC.

"No one has ever done a gene therapy study like this in cystic fibrosis before," said Dr. Deborah Gill of the Nuffield Department of Clinical Laboratory Sciences at Oxford University. "It’s a worldwide first in terms of the length of the study, the number of patients involved and the number of doses of gene therapy. By giving the therapy over a whole year, we will have the best chance yet of seeing an improvement in patients."

Professor Eric Alton, the coordinator for the consortium from Imperial College London, said: 'Conventional treatments have extended the life expectancy for people with cystic fibrosis. We’re hoping that this therapy will achieve a step change in the treatment of cystic fibrosis that focuses on the basic defect rather than just addressing the symptoms.

"This trial will assess if giving gene therapy repeatedly for a year will lead to the patients' lungs getting better. Eventually we hope gene therapy will push cystic fibrosis patients towards a normal life expectancy and improve their quality of life significantly."

Cystic fibrosis is an inherited disease that affects around 9,500 people in the UK. There is currently no cure and the only available treatments rely on alleviating the symptoms, not treating the underlying cause. The average life expectancy for cystic fibrosis patients is only 35 years.

The disease is caused by a single faulty gene that leads to thick, sticky mucus to build up in the lungs and digestive system.

The researchers in the UK Cystic Fibrosis Gene Therapy Consortium have developed a successful method for delivering a working copy of the defective gene directly into the lungs of patients.

The gene is administered via a nebulizer – much like inhalers used in asthma. Patients simply inhale a fine mist of fat globules which carry the DNA for the gene wrapped up inside.

The researchers have previously shown in smaller-scale that their nebulizer approach can get a working copy of the cystic fibrosis gene into the cells of the lung, and that the gene continues to work for a period of weeks and months.

The new clinical trial will assess whether the gene therapy can provide measurable clinical benefits for people with cystic fibrosis. That is: whether it can actually improve people’s lung function, and reduce the amount of mucus, inflammation and infection seen in patients.

Patients will be seen at the Royal Brompton Hospital, London, and the Western General Hospital and the Royal Hospital for Sick Children, Edinburgh.

The second lab-based study, with a further £1.2 million in funding from the MRC, will investigate a potentially more efficient delivery method for the gene therapy. The aim is to use a modified virus to carry the replacement gene into the lungs, which could lead to an even more effective treatment in the future.

Dr. Gill said: "The new virus delivery approach has never been tried before but it could be more efficient. It is specifically designed to deliver the gene therapy to the lungs, but it will take several more years of development before it gets to the point of human trials."

The consortium’s research, which has been supported by the Cystic Fibrosis Trust for a decade, had faced an uncertain future due a funding shortfall. The new funding from the MRC and NIHR will ensure the next stage of the research can continue as planned.

Professor Eric Alton of Imperial College London said: "With funding for this key part of the consortium's program secure, we will begin preparations for the trial immediately."

The outcome of the phase two trial will be known in spring 2014 and regular progress reports will be posted on the UK Cystic Fibrosis Gene Therapy ’s website.

Dr. Gill said: "A lot of patients in this country have either been directly involved in trials or in fundraising to support the research. That this new trial is going ahead is a really great result for everyone. It could find out if has a chance of working for all ."

Explore further: Breathe deep: Which patients could benefit from inhaled steroids in cystic fibrosis?

Related Stories

New drug hope for cystic fibrosis patients

September 9, 2008

A new drug therapy may represent a tremendous step forward in the treatment of some 70,000 cystic fibrosis (CF) patients worldwide, Dr David Sheppard from the University of Bristol will tell an audience at the BA Festival ...

Recommended for you

New method creates endless supply of kidney precursor cells

August 25, 2016

Salk Institute scientists have discovered the holy grail of endless youthfulness—at least when it comes to one type of human kidney precursor cell. Previous attempts to maintain cultures of the so-called nephron progenitor ...

Strict diet combats rare progeria aging disorders

August 25, 2016

Mice with a severe aging disease live three times longer if they eat thirty percent less. Moreover, they age much healthier than mice that eat as much as they want. These are findings of a joint study being published today ...

New avenue for understanding cause of common diseases

August 25, 2016

A ground-breaking Auckland study could lead to discoveries about many common diseases such as diabetes, cancer and dementia. The new finding could also illuminate the broader role of the enigmatic mitochondria in human development.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.